Zhiyuan Pharmaceutical files for Hong Kong IPO as profit falls and 397 million yuan redemption liability looms
The Wuxi drugmaker's revenue rose to 1.32 billion yuan in 2025, but net profit shrank and cash trailed potential buyback obligations tied to its 2025 Pre-IPO funding round.